Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
China Resources Double-Crane: Subsidiary Ganluol Injection Receives Approval Notice for Supplementary Drug Application
China Resources Shuanghe announced that its wholly-owned subsidiary Xi’an Jingxi Shuanghe Pharmaceutical Co., Ltd. has received the “Drug Supplement Application Approval Notice” from the National Medical Products Administration for Mannitol Injection, approving an additional 3000ml:150g specification.
Mannitol Injection, as a rinse agent, is used for intraurethral surgical rinsing to clear the visual field.
Jingxi Shuanghe’s current Mannitol Injection is 250ml:50g, and the company initiated the specification increase research in May 2023, submitted the application on August 15, 2023, and received approval on March 31, 2026.
The company has invested a total of RMB 1.4491 million in R&D for this drug.